Novel biomarkers to predict clinically beneficial therapies and avoid adverse outcomes are critically needed to advance the health of millions of patients with cardiovascular disease
Cardiovascular disease (CVD) remains the leading cause of mortality and healthcare expenditure in the world
More than 787,000 people in the US and 17.3 million globally die per year due to cardiovascular disease. Innovation in the field of cardiovascular health has stalled. This is due in part to our limited ability to understand an individual patient’s risk of cardiovascular disease and match their profile to the most effective therapy. This means that patients often receive therapies without benefit or don’t get the right drug at all. This has a significant associated cost for all of us; for example, the estimated cost of ineffective devices to treat Congestive Heart Failure is estimated to be 7bn dollars in the EU alone.